[Study results of primary therapy for head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].

[Study results of primary therapy for head and neck tumors : Highlights of the 2016 ASCO Annual Meeting].

HNO. 2016 Sep 13;

Authors: Gliese A, Busch CJ, Knecht R

Abstract
At the annual meeting of the American Society of Clinical Oncology (ASCO) 2016, results of current trials dealing with primary therapy for head and neck squamous cell carcinoma (HNSCC) were presented. Current trials investigate in particular therapy regimens for the treatment of locally advanced HNSCC. Concomitant chemoradiotherapy (CRT) remains the standard therapy approach. Current trials focus on sequential chemoradiation with modifications in induction chemotherapy (ICT) or the subsequent CRT schedule. Studies investigating the combination of targeted therapy with the epidermal growth factor receptor (EGFR) antibody cetuximab and concomitant, sequential, or adjuvant therapy were presented. The most important trials are summarized in this article.

PMID: 27624903 [PubMed - as supplied by publisher]

from #ENT-PubMed via ola Kala on Inoreader http://ift.tt/2d27jX3
via IFTTT